Daily Med News

SGLT2 and GLP-1 medications unlock new potential in CKM care

Recent data reveal a striking paradox: While 73% of endocrinologists prescribe glucose-lowering medications, fewer than 10% of nephrologists do.This difference highlights a critical opportunity. Historically, nephrologists have deferred metabolic management to primary care or endocrinology, but the interconnected reality of cardiovascular-kidney-metabolic (CKM) syndrome requires a more holistic approach.And because patients with advanced kidney disease see their nephrologist more frequently than…

Source: Healio News

About the author

David Miller

a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.

Leave a Comment

[mwai_chat window="true" fullscreen="true"]